Compare GLBE & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLBE | ALKS |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | Israel | Ireland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.7B |
| IPO Year | 2021 | 1991 |
| Metric | GLBE | ALKS |
|---|---|---|
| Price | $31.92 | $33.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | ★ $49.46 | $42.85 |
| AVG Volume (30 Days) | 1.5M | ★ 2.1M |
| Earning Date | 02-18-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.44 |
| EPS | 0.04 | ★ 2.02 |
| Revenue | $888,450,000.00 | ★ $1,521,338,000.00 |
| Revenue This Year | $29.23 | N/A |
| Revenue Next Year | $24.28 | $23.22 |
| P/E Ratio | $839.02 | ★ $16.50 |
| Revenue Growth | ★ 31.57 | 1.08 |
| 52 Week Low | $26.64 | $25.17 |
| 52 Week High | $63.69 | $36.45 |
| Indicator | GLBE | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 30.92 | 54.54 |
| Support Level | $31.69 | $33.04 |
| Resistance Level | $33.56 | $35.34 |
| Average True Range (ATR) | 1.55 | 1.03 |
| MACD | -0.24 | -0.21 |
| Stochastic Oscillator | 13.20 | 40.18 |
Global E Online Ltd provides e-commerce solutions. The company offers a platform to enable and accelerate direct-to-consumer cross-border e-commerce. The platform was purpose-built for international shoppers to buy seamlessly online and for merchants to sell from and anywhere in the world. The company localizes the shopper experience to make international transactions as seamless as domestic ones. The platform increases the conversion of international traffic into sales by removing much of the complexity associated with international e-commerce. The company derives maximum revenue from the United States.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.